NCT03575195View on ClinicalTrials.gov

Microbiota Intervention to Change the Response of Parkinson's Disease

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Parkinson Disease
Interventions
DRUG

Rifaximin

Rifaximin 550mg orally

OTHER

Placebo

Placebo control

Trial Locations (1)

94115

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Nova Southeastern University

OTHER

collaborator

Gateway Institute for Brain Research

INDUSTRY

lead

University of California, San Francisco

OTHER